Author Login

Correspondence to Author: Liast Walan Rinsky, Maan Sivlan. 

University for Modern Sciences and Arts (MSA), Giza 12451,Egypt.

Abstract:

Inhibitory autoantibodies against factor VIII (FVIII) are a hallmark of acquired hemophilia A (AHA), a rare and potentially fatal autoimmune disease that causes bleeding either spontaneously or as a result of trauma. In order to assess patient characteristics, therapies, and results, this study examines a single-center cohort. Methods: From 2012 to 2024, we looked back at the medical records of 22 adult patients who had been diagnosed with AHA.Demographics, clinical presentation, lab results, therapies, and results were all included in the data. Gender comparisons, treatment approaches, and remission results were assessed using statistical analysis. Results: The cohort’s average age was 62 years old, with a gender distribution of equal numbers (22–102 years). Pregnancy accounted for 27% of the suspected reasons, followed by cancer (23%), autoimmune disorders (5%), and idiopathic causes (45%).In 82% of cases, spontaneous cutaneous hematoma was the most frequent manifestation. Nine percent of cases involved severe bleeding that required hemostatic treatment. Forty-five percent of patients who had corticosteroid-based initial immunosuppressive therapy (IST) experienced remission; others needed subsequent Rituximab or Cyclophosphamide treatment. An individual with severe refractory bleeding was successfully treated with emicizumab, a new FVIIImimetic. Within a median of three months, 64% of patients experienced remission, whereas 14% experienced recurrence. Although corticosteroid adverse effects, including one hip fracture, were reported, no thrombotic events were observed. Conclusions: Although adverse effects call for customized management, IST continues to be the mainstay of AHA treatment. Emicizumab exhibits potential, especially in fragile populations and refractory patients..

Keywords: Emicizumab, Rituximab, acquired hemophilia, pregnancy-induced acquired hemophilia, and acquired bleeding disease.

Citation:

Dr.Liast Walan Rinsky, Acquired Hemophilia: A Review And Case Series. World Journal Of Biology 2025.